IVERIC bio - ISEE Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IVERIC bio in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ISEE shares.
View ISEE analyst ratings or view top-rated stocks.

9 brokerages have issued 12 month price objectives for IVERIC bio's stock. Their ISEE share price forecasts range from $18.00 to $35.00. On average, they expect the company's share price to reach $27.30 in the next year. This suggests a possible upside of 12.9% from the stock's current price.
View analysts price targets for ISEE or view top-rated stocks among Wall Street analysts.

IVERIC bio's stock was trading at $21.41 at the beginning of the year. Since then, ISEE stock has increased by 12.9% and is now trading at $24.17.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our ISEE earnings forecast.

IVERIC bio, Inc. (NASDAQ:ISEE) issued its earnings results on Wednesday, March, 1st. The company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.10. During the same quarter in the prior year, the firm earned ($0.29) earnings per share.

ETFs with the largest weight of IVERIC bio (NASDAQ:ISEE) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), ALPS Medical Breakthroughs ETF (SBIO), American Century Mid Cap Growth Impact (MID), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Principal Healthcare Innovators ETF (BTEC) and Harbor Health Care ETF (MEDI).

6 employees have rated IVERIC bio Chief Executive Officer Glenn Spina on Glassdoor.com. Glenn Spina has an approval rating of 41% among the company's employees. This puts Glenn Spina in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other IVERIC bio investors own include Pfizer (PFE), Inovio Pharmaceuticals (INO), Novavax (NVAX), Maxar Technologies (MAXR), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Alibaba Group (BABA), Cisco Systems (CSCO) and Kinross Gold (KGC).

IVERIC bio trades on the NASDAQ under the ticker symbol "ISEE."

IVERIC bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Avoro Capital Advisors LLC (5.59%), Price T Rowe Associates Inc. MD (4.01%), Alliancebernstein L.P. (3.51%), Braidwell LP (2.77%), Point72 Asset Management L.P. (2.46%) and Deutsche Bank AG (2.01%). Insiders that own company stock include Anthony S Gibney, Calvin W Roberts, Christopher Paul Simms, David Francis Carroll, David R Guyer, Glenn Sblendorio, Keith Westby and Pravin Dugel.
View institutional ownership trends.

Shares of ISEE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ISEE stock can currently be purchased for approximately $24.17.

IVERIC bio (NASDAQ:ISEE) has a market capitalization of $3.31 billion. The company earns $-185,210,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

IVERIC bio's mailing address is ONE PENN PLAZA 35TH FLOOR, NEW YORK NY, 10119. The official website for the company is ivericbio.com. The company can be reached via phone at (609) 474-6755 or via email at kathy.galante@ivericbio.com.